Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. - Wikidata - wikimedia - TriplyDB

Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats.

Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats.

http://www.wikidata.org/entity/Q42436464

about

Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation.Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.Gene-environment interactions: key to unraveling the mystery of Parkinson's disease Pesticides, microglial NOX2, and Parkinson's disease Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease.Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology Toxin-induced models of Parkinson's disease.Transcriptome analysis of a rotenone model of parkinsonism reveals complex I-tied and -untied toxicity mechanisms common to neurodegenerative diseases.Pathogenesis of Parkinson disease--the gut-brain axis and environmental factors.Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging.Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.A guide to neurotoxic animal models of Parkinson's disease Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease Classic and new animal models of Parkinson's disease.Mitochondrial dysfunction and oxidative stress promote apoptotic cell death in the striatum via cytochrome c/caspase-3 signaling cascade following chronic rotenone intoxication in rats Neurodegenerative disorders: Parkinson's disease and Huntington's disease Alterations of striatal glutamate transmission in rotenone-treated mice: MRI/MRS in vivo studies.Direct intranigral injection of dopaminochrome causes degeneration of dopamine neurons Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease.Adenosine A2A Receptor Blockade Prevents Rotenone-Induced Motor Impairment in a Rat Model of Parkinsonism.The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.Molecular pathogenesis, experimental models and new therapeutic strategies for Parkinson's disease.Animal models of Parkinson's disease progression Neurodegenerative diseases: neurotoxins as sufficient etiologic agents?Low dose rotenone treatment causes selective transcriptional activation of cell death related pathways in dopaminergic neurons in vivo.Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease.Mitochondrial toxins in Basal Ganglia disorders: from animal models to therapeutic strategies.Targeting the progression of Parkinson's disease.Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.Rational therapeutic approaches to progressive supranuclear palsy.Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease The pedunculopontine nucleus area: critical evaluation of interspecies differences relevant for its use as a target for deep brain stimulation.Tracking extranigral degeneration in animal models of Parkinson's disease: quest for effective therapeutic strategies.Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy.Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease models.Agrochemicals, α-synuclein, and Parkinson's disease.The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease.Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long-Standing Model.Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

P2860

Q24815148-3A0EE783-8F18-4B7D-AB01-BEA3E4A88735 Q26269955-126E888C-C571-4BA4-9088-C5DE0C5745BD Q28388674-72AC370C-7A33-47D3-BE1A-49601FFD69F5 Q28397585-9C0AB223-E5B9-4E00-A45A-3ACC510C93B0 Q33364885-F1F3531E-AEB1-4C4A-9B8D-4DABB80E4769 Q33603777-1993AF2A-2C1B-43B9-B10D-7B73159F38CA Q33844749-277E26D5-4B9E-46C1-97A2-C57BF9E9CC11 Q34412714-E3121885-913E-4351-8A3F-2D707FE65DF4 Q34674177-23743137-8D65-4124-AB90-824CE68C4264 Q34944292-00B2390F-E76C-4A5F-AE15-3C59A1A006A8 Q35181537-41431F21-9E3A-4383-9C2E-BC052ED163F6 Q35589979-8993E6AD-DE7D-4086-AD05-4C92DC89CB11 Q35603488-604B638C-8737-4CA3-B6D5-1F043AE2489B Q35863280-801959E7-B3DD-46EA-BC28-76A01CC23223 Q35875871-28DB8D97-93B2-4D95-8888-46AD8CC96993 Q36197290-88558862-E0D2-49B2-B13A-AC2C52AE943A Q36198011-089CFB18-0036-43BD-953A-F143094417DF Q36302933-9F50B50B-A8FE-4797-93BD-E11E1217F3E9 Q36505602-5D1DC7CA-544E-4B72-8843-E41A7D493506 Q36616362-0D352E37-133D-4C87-8080-669B81B9B21C Q36627429-C85A6F14-7F01-4386-8243-7EB48164F003 Q36709957-8E116629-6FE8-4F02-BE73-CC77B6A3D5B3 Q36883776-510E20D4-F5AF-4B5B-B502-47338B6EEA37 Q36924624-9046F9CE-9038-4CEA-9249-AB6358919004 Q36994301-9F58F6DC-DE8D-4B21-9283-7B3ED311262A Q37063461-35D007F0-B05D-4AA0-AC00-AAECF3AAFEE5 Q37110410-E7B1384F-D40B-4B14-B8E9-A6E554C3BF3F Q37211755-B4707AD6-59D2-4516-A2D7-F892A8F6CA26 Q37299619-E69C0A9F-C2F3-4D92-B62E-BB600F785673 Q37721641-A62FA5E7-FFC4-46B8-978B-1636B694A87D Q37753509-CE356C07-E92D-46EB-A6E4-2E254619AD4E Q37809751-FECCF10E-A4EA-47B3-893D-43462D6F6A89 Q37819451-1112CCC0-85C1-42B2-A4D0-8C902A667206 Q37880260-87B68888-7F11-4763-BEC1-0B2F928EEA77 Q37906364-3B24F789-7D06-42EA-A066-99BFA2582D60 Q38009051-E1FD4259-2CED-41D4-8E70-44CA7EA4C562 Q38039020-4366330C-9B57-4BC2-BAA7-445D6D2535B2 Q38202314-7B713F05-D121-4953-888C-2326F1B8BAF4 Q38366271-1E6FE3FD-2019-455C-8ED8-C1C4786383E3 Q38598375-630BF4F4-C9A7-4D5D-8414-BCABA9C24F91

P2860

Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats.

http://www.wikidata.org/entity/Q42436464

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Chronic systemic complex I inh ...... tisystem degeneration in rats.

@en

Chronic systemic complex I inh ...... tisystem degeneration in rats.

@nl

type

label

Chronic systemic complex I inh ...... tisystem degeneration in rats.

@en

Chronic systemic complex I inh ...... tisystem degeneration in rats.

@nl

prefLabel

Chronic systemic complex I inh ...... tisystem degeneration in rats.

@en

Chronic systemic complex I inh ...... tisystem degeneration in rats.

@nl

P1433

Q42436464-641F655D-A294-4332-A75A-91829FCCB257

P1476

Q42436464-5F3B7102-1DD9-4263-9B23-F7E6EE22078D

P2093

Q42436464-0010C0FF-B2FE-4037-BEE4-F330266FBADC

Q42436464-1B4AD1CF-5F8E-4A11-80F1-277CC33B700F

Q42436464-1C9BBC04-D906-4167-A4D6-991455737D4E

Q42436464-327B8F52-20D5-47D5-8213-993B1517A1AB

Q42436464-41533DCA-D66E-48A3-A82A-EB787DF07A73

Q42436464-5E042BBC-1E7F-4690-BEB2-FEFBC3F39C36

Q42436464-CD3D17FF-6C21-46CA-BB95-2801664F340C

P2860

Q42436464-0031E7D3-E9DF-4F2F-A92D-D12E11B0056B

Q42436464-059A5C41-6CED-4537-A686-52EA74C577EA

Q42436464-0642462C-1C35-4FC7-B0A7-D42ED075190F

Q42436464-0C7D32E2-2BC6-4399-85E3-C1DF56A85A3C

Q42436464-1586F5D0-B2D4-49B9-98C8-064082F69899

Q42436464-4097B18C-E80A-49B0-AD6E-EADF717D9AAB

Q42436464-60AD6C5A-D06C-41D9-9F3E-1C4FC006D292

Q42436464-6304F814-7D54-4D0A-B38B-6392F4467484

Q42436464-6714328D-E281-4B1D-A7F5-00B95B139D1E

Q42436464-79A91939-3D3B-44E6-AEB3-7CFCB754F921

P304

Q42436464-626DFE84-EC90-44BB-A1E5-2907F980443F

P31

Q42436464-39B63CB0-B546-4EFE-8A76-A017457A9A0A

P356

Q42436464-39D4F389-0228-4908-A5D9-D801D967DA3E

P407

Q42436464-E01A304F-29DF-47A3-BF48-C2D58DE50747

P433

Q42436464-D7B9B2C1-A7D6-4B68-810B-DC203B0A48B7

P478

Q42436464-8A7773D3-98A4-4B2F-9C65-976F435CC262

P50

Q42436464-499AF392-2349-4D6E-958B-820B9117AE07

Q42436464-74A00735-7E90-4E6A-8924-EC0FCC76FD69

P577

Q42436464-23A0E8C1-2DE5-4609-87B5-C540A6F75E2E

P5875

Q42436464-49A40FCF-1BAC-4473-B546-71918C31A979

P698

Q42436464-9531F67D-C842-458A-A8D0-4FCFFEFC9004

P356

J.1471-4159.2003.01533.X

P1433

Journal of Neurochemistry

P1476

Chronic systemic complex I inh ...... tisystem degeneration in rats.

@en

P2093

Annick Prigent

http://www.w3.org/2001/XMLSchema#string

Etienne C Hirsch

http://www.w3.org/2001/XMLSchema#string

Günter U Höglinger

http://www.w3.org/2001/XMLSchema#string

Jean Féger

http://www.w3.org/2001/XMLSchema#string

Karine Parain

http://www.w3.org/2001/XMLSchema#string

Merle Ruberg

http://www.w3.org/2001/XMLSchema#string

Pierre Champy

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy.

Further evidence for mitochondrial dysfunction in progressive supranuclear palsy.

Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy.

Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease.

Annonaceous acetogenins: recent progress.

Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease.

Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study. Caribbean Parkinsonism Study Group.

Basal ganglia neurotoxins.

[Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system].

P304

491-502

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1471-4159.2003.01533.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

Wolfgang H. Oertel

Patrick P Michel

P577

2003-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10924689

http://www.w3.org/2001/XMLSchema#string

P698

12558969

http://www.w3.org/2001/XMLSchema#string